PL367674A1 - Farmaceutyczne kompozycje adsorbatów bezpostaciowego leku - Google Patents
Farmaceutyczne kompozycje adsorbatów bezpostaciowego lekuInfo
- Publication number
- PL367674A1 PL367674A1 PL02367674A PL36767402A PL367674A1 PL 367674 A1 PL367674 A1 PL 367674A1 PL 02367674 A PL02367674 A PL 02367674A PL 36767402 A PL36767402 A PL 36767402A PL 367674 A1 PL367674 A1 PL 367674A1
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical compositions
- adsorbates
- amorphous drug
- amorphous
- drug
- Prior art date
Links
- 239000002156 adsorbate Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30026001P | 2001-06-22 | 2001-06-22 | |
PCT/IB2002/001792 WO2003000238A1 (en) | 2001-06-22 | 2002-05-21 | Pharmaceutical compositions of adsorbates of amorphous drug |
Publications (1)
Publication Number | Publication Date |
---|---|
PL367674A1 true PL367674A1 (pl) | 2005-03-07 |
Family
ID=23158346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL02367674A PL367674A1 (pl) | 2001-06-22 | 2002-05-21 | Farmaceutyczne kompozycje adsorbatów bezpostaciowego leku |
Country Status (29)
Country | Link |
---|---|
US (3) | US20030054037A1 (pl) |
EP (2) | EP2275091A1 (pl) |
JP (1) | JP4547148B2 (pl) |
KR (2) | KR100759635B1 (pl) |
CN (1) | CN1523979A (pl) |
AT (1) | ATE486586T1 (pl) |
AU (1) | AU2002302903B2 (pl) |
BG (1) | BG108489A (pl) |
BR (1) | BR0210519A (pl) |
CA (1) | CA2448825C (pl) |
CR (1) | CR7167A (pl) |
CZ (1) | CZ20033456A3 (pl) |
DE (1) | DE60238193D1 (pl) |
EA (1) | EA006777B1 (pl) |
EC (1) | ECSP034895A (pl) |
EE (1) | EE200400034A (pl) |
HU (1) | HUP0400281A3 (pl) |
IL (1) | IL158771A0 (pl) |
IS (1) | IS7018A (pl) |
MA (1) | MA27038A1 (pl) |
MX (1) | MXPA03010165A (pl) |
NO (1) | NO20035498D0 (pl) |
NZ (1) | NZ529490A (pl) |
OA (1) | OA12625A (pl) |
PL (1) | PL367674A1 (pl) |
SK (1) | SK15742003A3 (pl) |
TN (1) | TNSN03138A1 (pl) |
WO (1) | WO2003000238A1 (pl) |
ZA (1) | ZA200308735B (pl) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04007438A (es) | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
EP1474144B1 (en) * | 2002-02-01 | 2008-08-06 | Pfizer Products Inc. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
MXPA06001417A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
WO2005023225A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Cilostazol adsorbate |
ES2281594T3 (es) * | 2003-11-18 | 2007-10-01 | Helm Ag | Procedimiento para la preparacion de adsorbatos de atorvastatina en polvo de flujo libre. |
ES2274386T3 (es) * | 2004-02-06 | 2007-05-16 | Helm Ag | Preparaciones farmaceuticas que contienen tibolona amorfa. |
MY142989A (en) * | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
KR20070046892A (ko) * | 2004-08-31 | 2007-05-03 | 화이자 프로덕츠 인크. | 저용해도 약물 및 중합체를 포함하는 제약 투여형 |
GB2419094A (en) * | 2004-10-12 | 2006-04-19 | Sandoz Ag | Pharmaceutical composition of unpleasnt tasing active substances |
DE102004055229A1 (de) * | 2004-11-17 | 2006-05-18 | Heidelberger Druckmaschinen Ag | Zustandsabhängige Absicherung von Maschinen |
US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
CA2605214C (en) * | 2004-12-31 | 2016-07-12 | Reddy Us Therapeutics, Inc. | Benzylamine derivatives as cetp inhibitors |
US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
US20090005384A1 (en) * | 2005-01-25 | 2009-01-01 | Kowa Co., Ltd | Method for Producing Adsorptive Porous Body |
CA2594694A1 (en) | 2005-01-28 | 2006-08-03 | Pfizer Products Inc. | Drying of drug-containing particles |
US8617604B2 (en) * | 2005-02-03 | 2013-12-31 | Bend Research, Inc. | Pharmaceutical compositions with enhanced performance |
WO2006085217A2 (en) * | 2005-02-08 | 2006-08-17 | Pfizer Products Inc. | Solid adsorbates of hydrophobic drugs |
EP1767194A1 (de) * | 2005-06-09 | 2007-03-28 | Helm AG | Verfahren zur Herstellung von Adsorbaten des Drospirenons |
WO2008122048A2 (en) | 2007-04-02 | 2008-10-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Removal of contrast agents from blood |
BRPI0807939A2 (pt) * | 2007-04-03 | 2014-07-01 | Reddys Lab Ltd Dr | Formas sólidas de pemetrexed |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
CA2990445C (en) | 2007-08-21 | 2020-05-05 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
EP2072042A1 (en) * | 2007-12-21 | 2009-06-24 | Lek Pharmaceuticals D.D. | Active pharmaceutical ingredient on solid support, amorphous and with improved solubility |
EP2251038B1 (en) | 2008-03-11 | 2017-05-10 | ASKA Pharmaceutical Co., Ltd. | Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both |
CA2725484A1 (en) * | 2008-05-30 | 2009-12-03 | Eisai R&D Management Co., Ltd. | Percutaneously absorbable preparation |
ES2651948T3 (es) * | 2008-10-02 | 2018-01-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Administración de un polímero adsorbente para el tratamiento de la inflamación sistémica |
US8778401B2 (en) * | 2008-10-28 | 2014-07-15 | Agency For Science, Technology And Research | Mesoporous material excipients for poorly aqueous soluble ingredients |
KR101004205B1 (ko) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
JPWO2010092925A1 (ja) * | 2009-02-12 | 2012-08-16 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
WO2010102066A1 (en) * | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Dextran polymer powder for inhalation administration of pharmaceuticals |
EP2411137B1 (en) | 2009-03-27 | 2016-09-07 | Bend Research, Inc. | Spray-drying process |
EP2238979A1 (en) | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Active pharmaceutical ingredient adsorbed on solid support |
JP5775071B2 (ja) | 2009-06-16 | 2015-09-09 | ファイザー・インク | アピキサバンの製剤形 |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
WO2011110662A1 (en) * | 2010-03-11 | 2011-09-15 | Danmarks Tekniske Universitet | Supported biologically active compounds |
WO2011148253A2 (en) | 2010-05-25 | 2011-12-01 | Aurobindo Pharma Limited | Solid dosage forms of antipsychotics |
WO2012031133A2 (en) | 2010-09-03 | 2012-03-08 | Bench Research, Inc. | Spray-drying apparatus and methods of using the same |
EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
EP2618924A1 (en) | 2010-09-24 | 2013-07-31 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
TWI520732B (zh) * | 2011-01-18 | 2016-02-11 | 輝瑞有限公司 | 固體分子分散液 |
US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
WO2013025449A1 (en) * | 2011-08-16 | 2013-02-21 | Merck Sharp & Dohme Corp. | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
WO2013024358A2 (en) | 2011-08-18 | 2013-02-21 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors |
MX352074B (es) | 2011-09-27 | 2017-11-08 | Dr Reddys Laboratories Ltd | Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis. |
CN112402360A (zh) * | 2014-02-05 | 2021-02-26 | 斯洛文尼亚莱柯制药股份有限公司 | 雄激素受体拮抗剂的固体药物组合物 |
WO2016067132A1 (en) | 2014-10-31 | 2016-05-06 | Bend Research Inc. | Process for forming active domains dispersed in a matrix |
WO2016204058A1 (ja) * | 2015-06-15 | 2016-12-22 | 住友化学株式会社 | 有機el素子の製造方法 |
CN113476408A (zh) * | 2021-07-23 | 2021-10-08 | 兆科药业(广州)有限公司 | 一种苯丁酸甘油酯颗粒剂及其制备方法与应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
JPS5942313A (ja) * | 1982-09-01 | 1984-03-08 | Teijin Ltd | ポリビニルポリピロリドンを用いた製剤 |
EP0129893B1 (en) * | 1983-06-28 | 1991-09-04 | Takeda Chemical Industries, Ltd. | Ground mixture |
US4581232A (en) | 1983-07-20 | 1986-04-08 | Warner-Lambert Company | Magnesium trisilicate suitable for preparation of medicament adsorbates |
IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
US4711774A (en) * | 1986-03-27 | 1987-12-08 | Warner-Lambert Company | Medicament adsorbates with complex magnesium aluminum silicate and their preparation |
US4717565A (en) | 1986-03-27 | 1988-01-05 | Warner-Lambert Company | Process for the preparation of medicament adsorbates |
US4716033A (en) | 1986-03-27 | 1987-12-29 | Warner-Lambert Company | Medicament adsorbates with surfactant and their preparation |
US5015479A (en) | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
US4835186A (en) | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
IT1216570B (it) | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
IE60458B1 (en) | 1989-10-26 | 1994-07-13 | Elan Corp Plc | Enhanced bioavailability adsorbates |
US5300302A (en) | 1990-10-04 | 1994-04-05 | Nestec S.A. | Pharmaceutical composition in gel form in a dispensing package |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
US5626878A (en) * | 1995-01-10 | 1997-05-06 | Warner Lambert Company | Reduction of electrostatic forces between magnesium trisilicate adsorbates |
SI9500059A (sl) | 1995-02-23 | 1996-08-31 | Lek Tovarna Farmacevtskih | Postopek za pripravo trdnih površinskih disperzij amorfnih, v vodnih medijih slabo topnih učinkovin in njihova uporaba |
CA2218173A1 (en) | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogs of growth hormone-releasing factor |
AU6378796A (en) * | 1995-06-06 | 1996-12-24 | Warner-Lambert Company | Ranitidine salts on magnesium trisilicate as an adsorbate |
DE19532061A1 (de) * | 1995-08-31 | 1997-03-06 | Bayer Ag | N-Sulfonyliminodithioverbindungen |
DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
DE19627419A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Cycloalkano-pyridine |
US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
DE19704243A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | Neue 2-Amino-substituierte Pyridine |
DE19704244A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | 5-Hydroxy-alkyl substituierte Phenyle |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
KR100447553B1 (ko) | 1997-02-26 | 2004-09-08 | 화이자 인코포레이티드 | 헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 mip-1 알파의 ccr1 수용체로의 결합에 대한 선택적 저해제로서의 용도 |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
DE19832159A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Substituierte Tetrahydro-naphthaline |
DE19741399A1 (de) | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
DE19741400A1 (de) | 1997-09-19 | 1999-03-25 | Bayer Ag | Benzyl-biphenyle |
AU749958B2 (en) * | 1997-09-29 | 2002-07-04 | Beijing Huayi Chinese Pharmaceutical Factory | A (fagopyrum cymosum) (trev.) meisn composition, method to prepare and analyze the same and uses thereof |
IL137330A0 (en) | 1998-02-05 | 2001-07-24 | Pfizer Prod Inc | Novel dihydroxyhexanoic acid derivatives |
US6605624B1 (en) | 1998-02-13 | 2003-08-12 | Pharmacia Corporation | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
JPH11246404A (ja) | 1998-03-04 | 1999-09-14 | Taiho Yakuhin Kogyo Kk | 吸収を改善した医薬組成物 |
US20010025046A1 (en) | 1999-06-24 | 2001-09-27 | Rong(Ron) Liu | Self-emulsifying systems containing anticancer medicament |
EP2127642A3 (en) | 1998-08-13 | 2010-02-24 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
US6376481B2 (en) | 1998-09-02 | 2002-04-23 | Mcneil-Ppc, Inc. | Sterol esters in tableted solid dosage forms |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
AU6161099A (en) | 1998-09-25 | 2000-04-17 | Monsanto Company | Substituted n-aliphatic-n-aromatic (tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
DE69935992D1 (de) | 1998-09-25 | 2007-06-14 | Monsanto Co | Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins |
ES2310164T3 (es) * | 1999-02-10 | 2009-01-01 | Pfizer Products Inc. | Dispositivo de liberacion controlada por la matriz. |
WO2000056286A1 (en) * | 1999-03-19 | 2000-09-28 | Ranbaxy Laboratories Limited | Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil |
KR100342943B1 (ko) | 1999-08-04 | 2002-07-02 | 민경윤 | 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물 |
US20010053791A1 (en) * | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
AR027656A1 (es) * | 2000-03-16 | 2003-04-09 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US6602523B1 (en) | 2000-08-17 | 2003-08-05 | Technology Holding, Llc. | Composite material and process for increasing bioavailability and activity of a beneficial agent |
US6596262B2 (en) * | 2001-02-15 | 2003-07-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
-
2002
- 2002-05-21 EA EA200301279A patent/EA006777B1/ru not_active IP Right Cessation
- 2002-05-21 OA OA1200300326A patent/OA12625A/en unknown
- 2002-05-21 KR KR1020067021756A patent/KR100759635B1/ko not_active IP Right Cessation
- 2002-05-21 EP EP10175652A patent/EP2275091A1/en not_active Withdrawn
- 2002-05-21 CZ CZ20033456A patent/CZ20033456A3/cs unknown
- 2002-05-21 EE EEP200400034A patent/EE200400034A/xx unknown
- 2002-05-21 PL PL02367674A patent/PL367674A1/pl not_active Application Discontinuation
- 2002-05-21 NZ NZ529490A patent/NZ529490A/en unknown
- 2002-05-21 EP EP02730596A patent/EP1404302B1/en not_active Revoked
- 2002-05-21 DE DE60238193T patent/DE60238193D1/de not_active Expired - Lifetime
- 2002-05-21 MX MXPA03010165A patent/MXPA03010165A/es active IP Right Grant
- 2002-05-21 SK SK1574-2003A patent/SK15742003A3/sk not_active Application Discontinuation
- 2002-05-21 KR KR1020037017032A patent/KR100768766B1/ko not_active IP Right Cessation
- 2002-05-21 TN TNPCT/IB2002/001792A patent/TNSN03138A1/en unknown
- 2002-05-21 CN CNA028125037A patent/CN1523979A/zh active Pending
- 2002-05-21 AT AT02730596T patent/ATE486586T1/de not_active IP Right Cessation
- 2002-05-21 WO PCT/IB2002/001792 patent/WO2003000238A1/en active IP Right Grant
- 2002-05-21 IL IL15877102A patent/IL158771A0/xx unknown
- 2002-05-21 AU AU2002302903A patent/AU2002302903B2/en not_active Ceased
- 2002-05-21 CA CA002448825A patent/CA2448825C/en not_active Expired - Lifetime
- 2002-05-21 BR BR0210519-5A patent/BR0210519A/pt not_active IP Right Cessation
- 2002-05-21 JP JP2003506885A patent/JP4547148B2/ja not_active Expired - Fee Related
- 2002-05-21 HU HU0400281A patent/HUP0400281A3/hu unknown
- 2002-06-17 US US10/173,987 patent/US20030054037A1/en not_active Abandoned
-
2003
- 2003-11-10 ZA ZA200308735A patent/ZA200308735B/en unknown
- 2003-11-10 IS IS7018A patent/IS7018A/is unknown
- 2003-11-25 CR CR7167A patent/CR7167A/es not_active Application Discontinuation
- 2003-12-10 NO NO20035498A patent/NO20035498D0/no not_active Application Discontinuation
- 2003-12-11 EC EC2003004895A patent/ECSP034895A/es unknown
- 2003-12-11 MA MA27435A patent/MA27038A1/fr unknown
- 2003-12-22 BG BG108489A patent/BG108489A/bg unknown
-
2006
- 2006-12-04 US US11/566,408 patent/US8703199B2/en active Active
-
2008
- 2008-07-28 US US12/180,769 patent/US8389006B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL158771A0 (en) | Pharmaceutical compositions of adsorbates of amorphous drug | |
AU2003284251A1 (en) | Absorbent articles containing an activated carbon substrate | |
USD528656S1 (en) | Top surface of an absorbent article | |
WO2005011635A3 (en) | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials | |
AU2002360530A1 (en) | (5) helicene AND dibenzofluorene MATERIALS FOR USE IN ORGANIC LIGHT EMITTING DEVICES | |
AU2003277391A1 (en) | Semiconductor device with parallel plate trench capacitor | |
CA2395331A1 (en) | Pharmaceutical compositions providing enhanced drug concentrations | |
AU2003270019A1 (en) | Dental illumination device | |
AU2003253443A1 (en) | Monoaminofluorene compound and organic light-emitting device using the same | |
AU2003278233A1 (en) | Implantable mechanical device with adjustable geometry | |
AU2003220082A1 (en) | Thermionic vacuum diode device with adjustable electrodes | |
AU2002365360A1 (en) | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same | |
AU1904300A (en) | Improved organic led device | |
AU2002339150A1 (en) | Container with organic light emitting device | |
USD495082S1 (en) | Lamp with adjustable arm | |
AU2002352500A1 (en) | Absorbent articles with absorbent pad gapping | |
EP1697431B8 (en) | Boron-containing polymer compound and organic light emitting device using the same | |
AU2003292984A1 (en) | Amino-substituted oligothiophenes as organic semiconductor materials | |
AU2003223423A1 (en) | Bipolar transistor with graded base layer | |
EP1398497B8 (en) | Fuel injection device having injection hole plate | |
USD484229S1 (en) | Air freshener device | |
AU2003278456A1 (en) | Gum base composition | |
ATE469902T1 (de) | Amorphe substanz eines tricyclischen triazolobenzazepinderivats | |
AU2001217666A1 (en) | Silica-reinforced rubber compounded with an alkoxysilane and a strong organic base | |
AU2001258555A1 (en) | Castors with leveling device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |